Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04728893 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
A Phase 2 study of Non-Hodgkin's Lymphoma and Hematologic Malignancies, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 490
- Enrollment target
- 20
- Study locations
NCT04728893: Recruiting Phase 2 study of Non-Hodgkin's Lymphoma and Hematologic Malignancies, sponsored by Merck Sharp & Dohme.
NCT04728893 is a Phase 2 study of Non-Hodgkin's Lymphoma and Hematologic Malignancies that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 490 participants, above the 214-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (129% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04728893, a Phase 2 study of Non-Hodgkin's Lymphoma and Hematologic Malignancies, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 490 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).
Primary Outcome
DLTs will be defined as toxicities observed during the first 2 cycles (8 weeks) of Part 1 and include: Grade ≥3 nonhematologic toxicity (except Grade 3 nausea, vomiting, diarrhea, rash, fatigue, and uncontrolled hypertension which will not be considered a DLT unless lasting ≥72 hours despite optimal supportive care); Grade 4 hematologic toxicity lasting \>7 days (except Grade 3 lymphocytosis, Grade 4 platelet count decreased of any duration, or Grade 3 platelet count decreased if associated with
Conditions Studied
Interventions
- DRUG Nemtabrutinib
Study Locations (20)
Other
- FUNDALEU ( Site 0104) - Caba
- Hospital Privado Universitario de Córdoba ( Site 0107) - Córdoba
- Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 0110) - Mendoza
California
- University of California San Diego Moores Cancer Center ( Site 2717) - La Jolla
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site 2724) - Torrance
New Jersey
- Astera Cancer Care ( Site 2732) - East Brunswick
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 2704) - Hackensack
Arkansas
- Highlands Oncology Group ( Site 2728) - Springdale
Colorado
- Colorado Blood Cancer Institute ( Site 2726) - Denver
Kentucky
- The University of Louisville, James Graham Brown Cancer Center ( Site 2729) - Louisville
Minnesota
- Mayo Clinic - Rochester ( Site 2706) - Rochester
North Dakota
- Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 2708) - Fargo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 490 participants |
| Start Date | 2021-04-05 |
| Est. Completion | 2029-01-04 |
| Phase | Phase 2 |
What NCT04728893 shows while recruiting
NCT04728893 is an interventional study that assigns participants to a tested intervention. The registered 490 participants enrollment target is mid-sized for trials with a published cap, above the 214-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (129% higher).
The record links to 4 conditions, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Nemtabrutinib is the first listed.
NCT04728893 names 20 study sites across 16 states, led by Other, California, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04728893 about?
NCT04728893 is a clinical study titled "Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)". The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MC...
What is the current status of trial NCT04728893?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 490 participants. The study started on 2021-04-05. Estimated completion is 2029-01-04.
What conditions does trial NCT04728893 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma, Hematologic Malignancies, Chronic Lymphocytic Leukaemia, Waldenstroms Macroglobulinaemia.
What interventions are being tested in trial NCT04728893?
The interventions under investigation include: Nemtabrutinib (DRUG).
Who is sponsoring clinical trial NCT04728893?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04728893 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Kentucky, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04728893's enrollment target sits among peer trials
490 7th of 63 higher than 57 of 63 other Non-Hodgkin's Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin's Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cord Blood Transplant in Adults With Blood Cancers
RECRUITING · Phase 2
-
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
RECRUITING · Phase 2
-
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
RECRUITING · Phase 2
-
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
ACTIVE NOT RECRUITING · Phase 2
-
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06238479 · 490 participants · Phase 1
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
- NCT06336928 · 490 participants
A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis
- NCT06641414 · 490 participants · Phase 3
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
- NCT06875622 · 490 participants · NA
Remote Approaches for Optimizing Weight Loss (Elevate Weight Loss Trial)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI